ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

glaxosmithkline dungarvan limited - esomeprasool - gastroösofageaalne refluks - prootonpumba inhibiitorid - nexium control on näidustatud tagasijooksu sümptomite lühiajaliseks raviks (nt. kõrvetised ja hapniku regurgitatsioon) täiskasvanutel.

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

takeda pharma a/s - iksasomibtsitraat - mitu müeloomit - antineoplastilised ained - ninlaro kombinatsioonis lenalidomiidi ja deksametasooniga on näidustatud hulgimüeloomiga täiskasvanud patsientide raviks, kellel on vähemalt üks eelnevat ravi.

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - ritonaviir - hiv-nakkused - viirusevastased ravimid süsteemseks kasutamiseks - ritonaviir on näidustatud koos teiste retroviirusevastaste ravimitega hiv-1-infektsiooniga patsientide (täiskasvanud ja kaheaastased ja vanemad lapsed) raviks..

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

gilead sciences ireland uc - elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil dietüülfumaraat - hiv-nakkused - antivirals for treatment of hiv infections, combinations, antivirals for systemic use - ravi inimese immuunpuudulikkuse viiruse (hiv-1) 1 infektsiooni raviks täiskasvanutel vanuses 18 aastat ja üle kes on retroviiruste vastast ravi mittesaanud või nakatunud hiv 1 ilma teadaolevate vastavaks ühte kolmest retroviirusevastaseid stribild'i.

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

eli lilly nederland b.v. - duloksetiinvesinikkloriid - kusepidamatus, stress - psychoanaleptics, - yentreve on näidustatud naistele mõõduka kuni raskekujulise stressi kusepidamatuse (sui).

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

gilead sciences ireland uc - emtricitabine, rilpivirine vesinikkloriid, tenofovir alafenamide - hiv-nakkused - viirusevastased ravimid süsteemseks kasutamiseks - raviks täiskasvanutel ja noorukitel (vanuses 12 aastat ja vanemad koos kehakaalu vähemalt 35 kg) nakatunud inimese immuunpuudulikkuse viiruse (hiv-1) 1 ilma teadaolevate vastavaks mittenukleosiidsed pöördtranskriptaasi inhibiitorite (nnrti) klass, emtritsitabiini või tenofoviiri ja koos nakkav laadida ≤ 100 000 hiv-1 rna koopiat/ml.

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

janssen-cilag international nv - darunaviiri - hiv-nakkused - viirusevastased ravimid süsteemseks kasutamiseks - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

janssen-cilag international n.v. - darunavir, cobicistat - hiv-nakkused - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - rezolsta on näidustatud koos teiste retroviirusevastaste ravimitega inimese immuunpuudulikkuse viiruse 1 (hiv 1) nakkuse raviks 18-aastastel ja vanematel täiskasvanutel. genotypic katsetamine peaks juhendi kasutamine rezolsta.

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

pfizer limited - sunitiniib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastilised ained - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

janssen-cilag international nv - bedaakliini fumaraat - tuberkuloos, multidrug-resistentne - antimükobakterid - sirturo on näidustatud kasutamiseks osana asjakohase kombinatsiooni raviskeemi puhul kopsu multidrug resistentse tuberkuloosi (mdr-tb) täiskasvanud ja noorukieas patsientidel (12 aastat vähem kui 18-aastased ja kaaluvad vähemalt 30 kg) kui tõhus raviskeemi ei saa muul viisil, mis koosneb põhjustel vastupanu või talutavuse. tuleks arvesse võtta ametlikke juhiseid sobiva kasutada antibakteriaalseid aineid.